Received Feb 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 255T2 | IM / LA |
Patient experienced lower extremity weakness starting Tuesday 2/18/25 which progressed to full paralysis on Friday 2/21/25. Patient had no reflexes upon presentation at ER and underwent lumbar puncture. She received IGG with improvement in symptoms and no worsening or further paralysis.
UTI and sinus infection
Atrial fibrillation, depression, 1st year of remission breast cancer (received chemotherapy and immunotherapy in 2024), COPD
Eliquis 5 mg, Breztri Aerospace Inhaler, albuterol HFA inhaler, atorvastatin 40mg, ezetimibe 10 mg, sertraline 50 mg, montelukast 10 mg, carvedilol 12.5 mg, aspirin 81 mg, and Omega XL
no known allergies
Lumbar puncture with increased protein levels on 2/21/25